# OnCo record mucosal-melanoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/mucosal-melanoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "mucosal-melanoma" ;
  schema:name "Mucosal melanoma"@en ;
  schema:alternateName "Melanoma of mucous membranes"@en, "Sinonasal melanoma"@en, "Oral mucosal melanoma"@en, "Anorectal melanoma"@en, "Vulvovaginal melanoma"@en ;
  schema:description "Mucosal melanoma grows on the moist linings of the nose, mouth, anus or genital tract rather than on sun-exposed skin, so it is found late and carries fewer of the mutations that make skin melanoma visible to the immune system. Immunotherapy helps less often than in skin melanoma; a minority of tumours has a KIT mutation that the pill imatinib can target."@en ;
  schema:url <https://onco.cc/cancers/mucosal-melanoma/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Mucosal_melanoma> ;
  schema:citation <https://ascopubs.org/doi/10.1200/JCO.2016.67.9258>, <https://ascopubs.org/doi/10.1200/JCO.19.00210>, <https://en.wikipedia.org/wiki/Mucosal_melanoma> ;
  onco:tag "subtype-page" ;
  onco:related <https://onco.cc/cancers/acral-melanoma/>, <https://onco.cc/cancers/advanced-melanoma/>, <https://onco.cc/cancers/vulvar/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:targets <https://onco.cc/targets/kit/>, <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/mek/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/axitinib/>, <https://onco.cc/drugs/tunlametinib/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:pipeline <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/axitinib/>, <https://onco.cc/drugs/tunlametinib/>, <https://onco.cc/trials/nct06008106/>, <https://onco.cc/trials/seacraft-2/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/lifileucel/> ;
  onco:standardOfCare <https://onco.cc/terms/wide-local-excision/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/temozolomide/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/toripalimab/>, <https://onco.cc/drugs/axitinib/>, <https://onco.cc/drugs/imatinib/>, <https://onco.cc/drugs/nilotinib/>, <https://onco.cc/targets/kit/>, <https://onco.cc/drugs/tunlametinib/>, <https://onco.cc/trials/nct06008106/>, <https://onco.cc/trials/seacraft-2/>, <https://onco.cc/drugs/naporafenib/> .